Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

HIV treatment news

Show

From To
The UK’s largest sexual health clinic saw a 40% drop in new HIV infections this year

The clinic at 56 Dean Street in Soho, central London, the largest sexual health clinic in the UK, saw an unprecedented 40% drop in new HIV diagnoses

Published
22 December 2016
By
Gus Cairns
In the era of universal treatment, what are HIV clinical guidelines for?

The purpose and structure of clinical HIV guidelines may have to change radically now that universal treatment on diagnosis is the clinical consensus, physicians from the European

Published
22 December 2016
By
Gus Cairns
How close are we to a cure for HIV? A Q&A with HIV cure scientific superstars

What’s going on in HIV cure research? Is it ethical to take people off of HIV antiretrovirals if they participate in HIV cure research? These were some of the questions that lead researchers who are part of the amfAR Institute for HIV Cure Research at UCSF tackled at a forum on World AIDS Day this year.

Published
22 December 2016
From
BETA blog
British team studies initiation of treatment shortly after HIV diagnosis

A team of researchers in London, England, has reviewed the medical records of 113 men whose acute HIV infection was diagnosed at a sexual health clinic. The team found that most of the men (77%) initiated ART at their first clinic visit. Furthermore, they found that 99% of participants had an undetectable viral load within six months of initiating ART.

Published
21 December 2016
From
CATIE
GlaxoSmithKline’s New Drug Challenges HIV Treatment Orthodoxy

GlaxoSmithKline PLC’s ViiV Healthcare announced positive phase-three trial results for its new HIV drug in a dual-drug regimen, supporting the company’s audacious bet that it can shift the treatment orthodoxy away from three-drug combinations.

Published
20 December 2016
From
Wall Street Journal
Positive Results From First Phase III Studies of Investigational Two-Drug HIV Treatment Regimen

Janssen Sciences Ireland UC (Janssen) today announced that two Phase III studies to evaluate the safety and efficacy of switching virologically suppressed patients from a three or four drug (integrase inhibitor-, non-nucleoside reverse transcriptase inhibitor-, or boosted protease inhibitor-based) antiretroviral regimen to the two drug regimen of rilpivirine (Janssen) and dolutegravir (ViiV Healthcare) met the primary endpoint of non inferiority at week 48.

Published
20 December 2016
From
Janssen press release
High rates of injury found among some HIV-positive people in B.C.

Overall 14% of deaths among HIV-positive people were due to injury. In contrast, the figure among HIV-negative people was 6%. Furthermore, they stated that “the highest rates of injury among [HIV-positive] people were associated with falls and self-harm.” Among HIV-negative people, the top two causes of injury were “falls and motor vehicle accidents.”

Published
19 December 2016
From
CATIE
People With Multidrug-Resistant HIV Can Now Start Treatment on the Experimental Drug Ibalizumab

Ibalizumab is a new drug that is effective against drug resistant HIV. It is not approved for sale in the United States, but patients can take advantage of an expanded access program to start treatment right away.

Published
15 December 2016
From
TheBody.com
High prevalence of resistance to zidovudine among people in sub-Saharan Africa experiencing virological failure with tenofovir-containing ART

A significant proportion of people with virological failure after treatment with tenofovir-containing antiretroviral therapy (ART) have resistance to thymidine analogues (stavudine and zidovudine), and in many cases other

Published
15 December 2016
By
Michael Carter
Charlie Sheen Achieves Undetectable Viral Load With Weekly Injectable HIV Treatment

Actor Charlie Sheen revealed this month that he has achieved an undetectable viral load by taking PRO 140, an injectable HIV drug that's currently being studied. Sheen started taking PRO 140 as a study participant in a phase-3 clinical trial that is looking into the drug's safety and effectiveness in humans.

Published
08 December 2016
From
The Body

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.